Related Articles
First clinical experience with CDK4/6 inhibitors in breast cancer therapy
CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
Palbociclib added to ongoing endocrine therapy for hormone receptor‑positive HER2‑negative metastatic breast cancer: A case report series
Severe hypoglycaemia under abemaciclib administration in a patient with breast cancer: A case report
Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion